Sujata Tewari, BA, previously of the Medical Practice Evaluation Center (MPEC) at Massachusetts General Hospital, and Andrea ...

ORLANDO, Fla. — As the Trump administration works to slim down government spending, that includes millions of dollars in funding for HIV medications. LGBT+ Center Orlando was established in 1978. The ...

A new study led by researchers at Emory University's Rollins School of Public Health, published Monday by JAMA Network Open, ...

The annual report, published by the European Centre for Disease Prevention and Control (ECDC), was released on 27 November ...

CIVIL society activists have called on the South African government to take decisive action, criticizing the United States for what they describe as “bullying” and a token donation of the breakthrough ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read more on GILD stock here.

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Aaron Schatzman, 43, sits after support group at Shepherd Wellness Community, Friday, Nov. 7, 2025, in Bloomfield. Schatzman says his life was changed by finding other people in the HIV community and ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at Amsterdam UMC investigated whether this dysregulation can be prevented by ...

Some lawmakers and advocates are increasingly uncertain whether critical HIV and AIDS services will survive the federal government’s funding fight. The GOP’s House-passed budget bill seeks to cut over ...

The U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion. Product sales decreased 2% to $7.3 billion, primarily driven by lower Veklury (remdesivir) and Cell ...